News
The death will likely further stoke safety concerns around Sarepta's gene therapies, as well as raise questions around the ...
Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, ...
According to multiple reports, a 51-year-old man with limb-girdle muscular dystrophy died from acute liver failure after ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...
Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...
19h
MedPage Today on MSNDuchenne Gene Therapy Will Undergo Changes After Patient DeathsAt the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...
A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...
Lab study findings increase understanding of the molecular mechanisms underpinning vitamin D deficiency and highlight SDR42E1 ...
The Purdy family shares their insights on navigating their child’s rare neurodegenerative disease and their direct ...
A third patient has died from acute liver failure after receiving a gene therapy treatment from Sarepta Therapeutics, the biotech company confirmed to Bloomberg on July 18. The patient died while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results